Evidence map›Paper›PMID 41093240›Full record

ReviewAdvanced drug delivery reviews2025

Opportunities for machine learning and artificial intelligence in physiologically-based pharmacokinetic (PBPK) modeling.

Anne M Talkington, Yanguang Cao, Anthony J Kearsley, Samuel K Lai

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Therapeutic peptides and proteins: Status and developments in drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anne M TalkingtonApplied and Computational Mathematics Division, National Institute of Standards and Technology, Gaithersburg, MD, USA; Division of Pharmacokinetics, Pharmacodynamics, and Systems Pharmacology, Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, NY, USA. Electronic address: annetalk@buffalo.edu.
Yanguang CaoDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, NC, USA.
Anthony J KearsleyApplied and Computational Mathematics Division, National Institute of Standards and Technology, Gaithersburg, MD, USA.
Samuel K LaiDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA; Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC, USA; Department of Immunology and Microbiology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: lai@unc.edu.

Funding

Quantitative Systems Pharmacology of Antibody Therapeutics across Diverse Biological ContextsR35GM152449 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Yanguang Cao · 2024 to 2026
$1.2M
NIGMS NIH HHS R35 GM152449
6 · The paper itself

Abstract

Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool for quantitating and understanding the fate of drug and drug carriers in complex living systems. It is particularly valuable in situations where data are difficult to obtain due to cost, time, or ethical constraints. Recent advances in PBPK modeling have greatly improved their accuracy in modeling in vivo and clinical data, especially in special populations (e.g., pediatric and geriatric subjects), which consequently enhanced their utility in drug development. Nevertheless, current PBPK models remain limited by our ability to ascertain complex biological mechanisms and/or physiological processes, often resulting in many critical but unknown parameters or parameters with large uncertainty. Machine learning (ML) and applications of broader artificial intelligence (AI) tools that facilitate parameter estimation, model learning, database mining, and uncertainty quantification not only offer the potential to address the shortcomings of PBPK modeling, but also introduce opportunities for enabling earlier use of PBPK modeling in the drug development process. Here, we summarize ML-influenced advances in PBPK modeling and discuss our expectations of the likely avenues for future ML/AI contributions to PBPK modeling.

Indexed as

Artificial IntelligenceMachine LearningModels, BiologicalPharmacokineticsAnimalsDrug DevelopmentHumansPharmaceutical PreparationsPharmaceutical PreparationsArtificial intelligenceMachine learningPhysiologically-based pharmacokinetic modeling

Identifiers

PMID41093240
PMCPMC12573771

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.